Market closed
Janux Therapeutics/$JANX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Janux Therapeutics
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Ticker
$JANX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
81
Website
JANX Metrics
BasicAdvanced
$1.8B
-
-$1.28
3.22
-
Price and volume
Market cap
$1.8B
Beta
3.22
52-week high
$65.60
52-week low
$22.52
Average daily volume
885K
Financial strength
Current ratio
59.205
Quick ratio
59.027
Long term debt to equity
2.08
Total debt to equity
2.251
Management effectiveness
Return on assets (TTM)
-8.57%
Return on equity (TTM)
-10.09%
Valuation
Price to revenue (TTM)
157.63
Price to book
1.79
Price to tangible book (TTM)
1.79
Price to free cash flow (TTM)
-37.783
Growth
Revenue change (TTM)
30.99%
Earnings per share change (TTM)
-3.08%
3-year revenue growth (CAGR)
42.79%
3-year earnings per share growth (CAGR)
-2.59%
What the Analysts think about JANX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Janux Therapeutics stock.
JANX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
JANX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
JANX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Janux Therapeutics stock?
Janux Therapeutics (JANX) has a market cap of $1.8B as of April 29, 2025.
What is the P/E ratio for Janux Therapeutics stock?
The price to earnings (P/E) ratio for Janux Therapeutics (JANX) stock is 0 as of April 29, 2025.
Does Janux Therapeutics stock pay dividends?
No, Janux Therapeutics (JANX) stock does not pay dividends to its shareholders as of April 29, 2025.
When is the next Janux Therapeutics dividend payment date?
Janux Therapeutics (JANX) stock does not pay dividends to its shareholders.
What is the beta indicator for Janux Therapeutics?
Janux Therapeutics (JANX) has a beta rating of 3.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.